-
Mashup Score: 5Everolimus Plus Lanreotide Extends PFS in Patients With Aggressive Gastroenteropancreatic Neuroendocrine Tumors - 2 hour(s) ago
The phase 3 STARTER-NET trial found that everolimus plus lanreotide more than doubles progression-free survival among patients with aggressive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) versus everolimus therapy alone, and has a manageable safety profile (Abstract 652). The trial focused on patients with unresectable or recurrent grade 1 or 2 GEP-NETs with poor prognostic factors, for whom effective treatments are currently lacking.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2
Udhayvir Grewal: Excellent discussion on TNT in gastric cancer / ASCO GI 2025, cancer, gastric cancer, Mayo Clinic, MD Anderson Cancer Center, OncoDaily,
Source: oncodaily.comCategories: General Medicine News, Partners & KOLsTweet-
RT @OncoDailyGI: Excellent discussion on TNT in gastric cancer - @UGrewalMD @ASCO https://t.co/6P44t9SuKA #Cancer #GIOnc #GI25 #GastricC…
-
-
Mashup Score: 9ASCO Gastrointestinal Cancers Symposium - Research Summaries for - 3 hour(s) ago
Visit this page during the meeting to find patient-friendly summaries of highlighted research.
Source: society.asco.orgCategories: General Medicine News, Partners & KOLsTweet-
New #NETCancer research from #GI25: Combination of everolimus and lanreotide helps patients with GEP-NETs live longer without cancer growth compared to everolimus alone. Read a plain language summary from us: https://t.co/K1CKNQMNEk
-
-
Mashup Score: 4ASCO Applauds New Draft Guidance on Including Tissue Biopsies in - 5 hour(s) ago
ASCO welcomes new draft guidance on including tissue biopsies in clinical trials.
Source: society.asco.orgCategories: General Medicine News, Partners & KOLsTweet-
We applaud new draft guidance from @FDA & OHRP on incl tissue biopsies in clinical trials. In @TheCancerLetter editorial we stated guidance closely aligns w our ongoing efforts to improve ethics of research biopsies, esp biopsies that are mandatory. More: https://t.co/SUOnWnOQ9s https://t.co/otht8T9NYp
-
-
Mashup Score: 0Quality-of-Life and Geriatric Assessments Correlate With Survival in Elderly Patients With Pancreatic Cancer - 6 hour(s) ago
The GIANT trial secondary analysis shows that baseline quality of life and geriatric assessments strongly correlate with survival outcomes in elderly patients with newly diagnosed metastatic pancreatic adenocarcinoma treated with dose-reduced chemotherapy (Abstract 676).
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
Quality of life evaluations & geriatric assessments are strongly correlated w/ survival in vulnerable older patients w/ newly diagnosed metastatic #PancreaticCancer, according to new data presented at #GI25: https://t.co/XPBD2pn9Tm https://t.co/8RlC2zz6Vs
-
-
Mashup Score: 8Gastrointestinal Cancers Symposium | ASCO Daily News - 1 day(s) ago
The latest scientific coverage and expert insights from the ASCO Gastrointestinal Cancers Symposium, all in one place.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
Research from #GI24 is now available! #ASCODailyNews is covering just-released abstracts from the upcoming Symposium, and you can read all the advance articles now: https://t.co/A037RntyKB #gicsm #OncTwitter https://t.co/kwyFjBDCEr
-
-
Mashup Score: 10Gynecologic Cancer - 2 day(s) ago
Gynecologic Cancer
Source: society.asco.orgCategories: General Medicine News, Partners & KOLsTweet-
Check out our new guideline update, Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer. Read more: https://t.co/JmE7OkXc6p https://t.co/U5P5dlx6Qe
-
-
Mashup Score: 32Program Guide – ASCO Meeting Program Guide - 3 day(s) ago
For unresectable locally advanced or metastatic HER2-negative gastric cancer (GC), the combination of chemotherapy with immunotherapy, specifically PD-1 inhibitors, has emerged as a new standard of care in first-line treatment of advanced GC, but the patients’ outcomes remain poor. Early clinical studies investigating the combination of immunotherapy with anti-angiogenic drugs have demonstrated favorable efficacy. Therefore, it is worth exploring whether the addition of fruquintinib, a potent VEGFR-1,2,3
Source: meetings.asco.orgCategories: General Medicine News, Partners & KOLsTweet-
The #GI25 abstracts are now available! Late-Breaking Abstracts (LBAs) will be released at 7:00 AM PT on their day of presentation. Check out the latest practice-changing science in GI cancers here: https://t.co/82LqTOPiS8 Co-sponsored by @AmerGastroAssn, @ASTRO_org, @SocSurgOnc https://t.co/31o07rYmom
-
-
Mashup Score: 79
The American Society of Clinical Oncology applauds Dr. Monica M. Bertagnolli for her service as the 17th Director of the National Institutes of Health and Dr. Kimryn Rathmell as the 17th director of
Source: society.asco.orgCategories: General Medicine News, Partners & KOLsTweet-
ASCO applauds Dr. Monica M. Bertagnolli for her service as the 17th Director of @NIH & Dr. Kimryn Rathmell for her service as the 17th director of the @TheNCI. Thank you both for your leadership! More: https://t.co/t6mUygbtRX https://t.co/raH4uyn8P8
-
-
Mashup Score: 9States Convene for 2025 Legislative Session - 7 day(s) ago
All fifty states and Washington, D.C. will convene for legislative sessions in 2025. New Jersey and Virginia will enter the second year of their biennia; all other states will be entering their first
Source: society.asco.orgCategories: General Medicine News, Partners & KOLsTweet-
ASCO is celebrating 10 years of our state advocacy program! Thank you to all the State Affiliates and ASCO volunteers for their dedication over the last decade. #ASCOAdvocacy The work continues as the 2025 state sessions begin! https://t.co/r7idlS591Y https://t.co/LwuHfIE69o
-
New research just presented at #GI25: STARTER-NET trial shows everolimus + lanreotide more than doubles PFS vs everolimus monotherapy among pts w/ aggressive GEP-NETs: https://t.co/LyF50SL8UI #ASCODailyNews #GICSM https://t.co/k6CBAIzzut